Evaluation of Vestibular Stimulation to Help Occasional Sleeplessness (VSOM)
Primary Purpose
Insomnia, Sleeplessness, Transient Insomnia
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Electric stimulation of the Vestibular Nerve - "VirtuSom"
Electric stim of the Vestibular Nerve - "VirtuSom" - SHAM
Sponsored by
About this trial
This is an interventional treatment trial for Insomnia focused on measuring Electric Stimulation, Latency to Persistent Sleep (LPS), Transient Insomnia, Insomnia
Eligibility Criteria
Inclusion Criteria:
- Males and females, ages 21- 50 attempts will be made to enroll equal distributions of males and females
- Able and willing to provide written informed consent
- Self reported habitual bedtime between 2100 and 0100 hours, which does not vary by more than 1 hour at least 5 nights per week
- Self reported 7.5-9 hrs. habitual sleep time
- Able to commit to 9 hrs of sleep opportunity throughout the study, but especially for the 3 nights prior to their PSG
- Pass Berlin questionnaire, i.e. low likelihood of sleep disordered breathing
- No history or evidence of RLS(restless leg syndrome) /PLMS (periodic limb movement syndrome) /Narcolepsy, no non-respiratory related sleep disorders.
Exclusion Criteria:
- Regular use of a pack or more per day of tobacco products
- Typically consumes more than 2 (12 oz) caffeinated beverages per day
- Self reported history of motion sickness
- Participation in a study of investigational or marketed drugs or devices during the 30-day period prior to the start of the study or during the study
- Clinically significant medical or psychiatric condition as determined by the investigator
- Probable diagnosis of a current sleep disorder including but not limited to insomnia, sleep apnea, restless legs syndrome, or periodic limb movement disorder
- History of current or recent (e.g. within past 5 years) alcohol, narcotic or any other drug abuse as defined by the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association, 4th Edition (DSM-IV)
- Currently works night shift or rotating shift
- Travel or planned travel across more than 1 time zone within one week prior to randomization
- Use of any medication that, in the opinion of the investigator, may alter sleep or wakefulness. (See Appendix E: Guideline For Medications Commonly Associated With Alterations Of Sleep / Wake Functioning). Subjects will undergo urine drug testing.
- Consumption of more than 14 alcoholic drinks per week, or the recent consumption of more than 4 alcoholic drinks in one night. Subjects will be tested for alcohol, using a saliva test kit.
- Pregnancy (will confirm absence of pregnancy with a urine or serum pregnancy test in women's of child bearing age).
- Presence of a pacemaker
- Presence of epilepsy or other uncontrolled medical conditions.
- Prior participation in a VirtuSom protocol
- History of vestibular disorders, (such as vertigo)
Sites / Locations
- Neuro Trials
- Sleep Disorders Center of Georgia
- Clinilabs
- University of Rochester
- Duke University Medical Center
- Tri-State Sleep Disorders Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Group 1- "VirtuSom" - Stim
Group 2- "VirtuSom"- Sham
Arm Description
Normal sleepers (7.5 - 9.0 hours), MSLT (multiple sleep latency test) >=14 min; phase-advance 5-hours studied under full polysomnogram (PSG) with active device (electric stimulation of the Vestibular nerve).
Normal sleepers (7.5 - 9.0 hours), MSLT >=14 min; phase-advance 5-hours studied under full polysomnogram (PSG) with placebo / sham device (NO electric stimulation of the Vestibular nerve).
Outcomes
Primary Outcome Measures
Latency to Persistent Sleep (LPS)
Latency to Persistent Sleep is how long does it take for a person to fall asleep and stay asleep. This is measured in minutes. This is different from sleep onset latency as participants fall asleep, but may wake back up.
Secondary Outcome Measures
Subjective Sleep Onset Latency (SOL)
Subjective sleep onset latency is how long it took a person to fall asleep once lights out. For subjective SOL this is a question to a participant the next morning asking how long they felt it took them to fall asleep in minutes.
Total Sleep Time (TST) in the First 2 Hours After Lights Out
Total sleep time is the total amount of sleep a person gets in minutes over the course of the night. For this outcome measure it is for the 2 hours after lights out.
Total Sleep Time (TST) in the First Hour After Lights Out
Total sleep time is the total amount of sleep a person gets in minutes over the course of the night. For this outcome measure it is the total amount of sleep a participant gets over the first hour of sleep after lights out.
Scored Sleep Onset Latency (SOL on PSG)
Sleep onset latency is the amount of time it takes to fall asleep after the lights have been turned off. For this outcome measure it is as measured by the scored PSG.
Full Information
NCT ID
NCT00594022
First Posted
December 26, 2007
Last Updated
December 13, 2018
Sponsor
Philips Respironics
1. Study Identification
Unique Protocol Identification Number
NCT00594022
Brief Title
Evaluation of Vestibular Stimulation to Help Occasional Sleeplessness
Acronym
VSOM
Official Title
The Effect of Vestibular Stimulation on Transient Insomnia Induced by a Five-hour Phase Advance of Sleep Time
Study Type
Interventional
2. Study Status
Record Verification Date
December 2018
Overall Recruitment Status
Completed
Study Start Date
October 2007 (undefined)
Primary Completion Date
June 2008 (Actual)
Study Completion Date
July 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Philips Respironics
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine whether a small electrical current to the vestibular nerve (balance organ) will decrease the time it take for participants to fall asleep.
Detailed Description
This 2 arm study will look at the proposed treatment (electrical stimulation of the vestibular nerve) versus a sham or placebo device. The effect of the device will be evaluated in a study that uses normal sleepers and advances them(puts them to bed 5-hours earlier than normal) to see if they fall asleep faster in one group or the other. Stimulation in the treated or sham group is only for the first hour after lights off.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insomnia, Sleeplessness, Transient Insomnia
Keywords
Electric Stimulation, Latency to Persistent Sleep (LPS), Transient Insomnia, Insomnia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
349 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Group 1- "VirtuSom" - Stim
Arm Type
Active Comparator
Arm Description
Normal sleepers (7.5 - 9.0 hours), MSLT (multiple sleep latency test) >=14 min; phase-advance 5-hours studied under full polysomnogram (PSG) with active device (electric stimulation of the Vestibular nerve).
Arm Title
Group 2- "VirtuSom"- Sham
Arm Type
Placebo Comparator
Arm Description
Normal sleepers (7.5 - 9.0 hours), MSLT >=14 min; phase-advance 5-hours studied under full polysomnogram (PSG) with placebo / sham device (NO electric stimulation of the Vestibular nerve).
Intervention Type
Device
Intervention Name(s)
Electric stimulation of the Vestibular Nerve - "VirtuSom"
Intervention Description
This device is similar to a Tens or Micro-Current electrical stimulator with respect to current levels deliver; however, because of the location of the stimulation it is similar to a Cranial Electrical Stimulator. A small electric stimulation (100 uA - 1000 uA) will be provided at the mastoids (bi-laterally) via small hydrogel electrodes.
Intervention Type
Device
Intervention Name(s)
Electric stim of the Vestibular Nerve - "VirtuSom" - SHAM
Intervention Description
This device is similar to a Tens or Micro-Current electrical stimulator with respect to current levels deliver; however, because of the location of the stimulation it is similar to a Cranial Electrical Stimulator. For the Sham Group, NO electric stimulation (100 uA - 1000 uA) will be provided at the mastoids (bi-laterally) via small hydrogel electrodes. This is a sham / placebo device only.
Primary Outcome Measure Information:
Title
Latency to Persistent Sleep (LPS)
Description
Latency to Persistent Sleep is how long does it take for a person to fall asleep and stay asleep. This is measured in minutes. This is different from sleep onset latency as participants fall asleep, but may wake back up.
Time Frame
Treatment Night
Secondary Outcome Measure Information:
Title
Subjective Sleep Onset Latency (SOL)
Description
Subjective sleep onset latency is how long it took a person to fall asleep once lights out. For subjective SOL this is a question to a participant the next morning asking how long they felt it took them to fall asleep in minutes.
Time Frame
Treatment night
Title
Total Sleep Time (TST) in the First 2 Hours After Lights Out
Description
Total sleep time is the total amount of sleep a person gets in minutes over the course of the night. For this outcome measure it is for the 2 hours after lights out.
Time Frame
Treatment night
Title
Total Sleep Time (TST) in the First Hour After Lights Out
Description
Total sleep time is the total amount of sleep a person gets in minutes over the course of the night. For this outcome measure it is the total amount of sleep a participant gets over the first hour of sleep after lights out.
Time Frame
Treatment night
Title
Scored Sleep Onset Latency (SOL on PSG)
Description
Sleep onset latency is the amount of time it takes to fall asleep after the lights have been turned off. For this outcome measure it is as measured by the scored PSG.
Time Frame
Treatment Night
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Males and females, ages 21- 50 attempts will be made to enroll equal distributions of males and females
Able and willing to provide written informed consent
Self reported habitual bedtime between 2100 and 0100 hours, which does not vary by more than 1 hour at least 5 nights per week
Self reported 7.5-9 hrs. habitual sleep time
Able to commit to 9 hrs of sleep opportunity throughout the study, but especially for the 3 nights prior to their PSG
Pass Berlin questionnaire, i.e. low likelihood of sleep disordered breathing
No history or evidence of RLS(restless leg syndrome) /PLMS (periodic limb movement syndrome) /Narcolepsy, no non-respiratory related sleep disorders.
Exclusion Criteria:
Regular use of a pack or more per day of tobacco products
Typically consumes more than 2 (12 oz) caffeinated beverages per day
Self reported history of motion sickness
Participation in a study of investigational or marketed drugs or devices during the 30-day period prior to the start of the study or during the study
Clinically significant medical or psychiatric condition as determined by the investigator
Probable diagnosis of a current sleep disorder including but not limited to insomnia, sleep apnea, restless legs syndrome, or periodic limb movement disorder
History of current or recent (e.g. within past 5 years) alcohol, narcotic or any other drug abuse as defined by the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association, 4th Edition (DSM-IV)
Currently works night shift or rotating shift
Travel or planned travel across more than 1 time zone within one week prior to randomization
Use of any medication that, in the opinion of the investigator, may alter sleep or wakefulness. (See Appendix E: Guideline For Medications Commonly Associated With Alterations Of Sleep / Wake Functioning). Subjects will undergo urine drug testing.
Consumption of more than 14 alcoholic drinks per week, or the recent consumption of more than 4 alcoholic drinks in one night. Subjects will be tested for alcohol, using a saliva test kit.
Pregnancy (will confirm absence of pregnancy with a urine or serum pregnancy test in women's of child bearing age).
Presence of a pacemaker
Presence of epilepsy or other uncontrolled medical conditions.
Prior participation in a VirtuSom protocol
History of vestibular disorders, (such as vertigo)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrew Krystal
Organizational Affiliation
Duke University Medical Center, Duke Clinic Sleep Lab
Official's Role
Principal Investigator
Facility Information:
Facility Name
Neuro Trials
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30342
Country
United States
Facility Name
Sleep Disorders Center of Georgia
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30342
Country
United States
Facility Name
Clinilabs
City
New York
State/Province
New York
ZIP/Postal Code
10019
Country
United States
Facility Name
University of Rochester
City
Rochester
State/Province
New York
ZIP/Postal Code
14642
Country
United States
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
Tri-State Sleep Disorders Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45246
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Evaluation of Vestibular Stimulation to Help Occasional Sleeplessness
We'll reach out to this number within 24 hrs